id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-296631-43z3ee8m	de Feria, Alejandro	ACE inhibitors/ARB use and COVID-19. Time to change practice or keep gathering data?	2020-07-04		.txt	text/plain	896	70	60	This mechanism of entry, in combination with the findings of the previously mentioned risk factors, raised concerns that angiotensin-converting enzyme inhibitors (ACEi) and angiotensin receptor blockers (ARBs) could increase both the susceptibility and severity of SARS CoV-2 infection. An international, multicenter study which included electronic records from 169 hospitals in 11 countries on three continents again confirmed that advanced age (>65), heart failure, coronary disease, and hypertension (among other factors) increased risk for in hospital mortality with COVID-19, but ACEi/ARB therapy showed no harm [4] . In contrast to these findings, early studies out of China suggested that ARB therapy may improve clinical outcomes in COVID-19 infection [5, 6] . The current study is unique in that it focuses on patients with "severe COVID" disease and found that chronic ACE inhibitor and ARB use was associated with an increased risk of acute kidney injury, as well as a signal for a dosage effect.	./cache/cord-296631-43z3ee8m.txt	./txt/cord-296631-43z3ee8m.txt